Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled ‘A Retrospective Study to Evaluate the Real-World Effectiveness of Lorlatinib Among ROS1-Positive NSCLC Patients.’ The study aims to assess the effectiveness of lorlatinib, a treatment for non-small cell lung cancer (NSCLC) that has spread and is difficult to control. This research is significant as it could provide insights into the safety and efficacy of lorlatinib for patients with ROS1-positive NSCLC who have undergone previous treatments.
The intervention being tested is lorlatinib, an ALK/ROS1 tyrosine kinase inhibitor. It is administered orally and is intended to manage advanced or metastatic NSCLC in patients with the ROS1 gene mutation.
This observational study follows a cohort model with a retrospective time perspective. The primary focus is to observe and document patient experiences with lorlatinib to determine its real-world effectiveness.
The study began on November 5, 2024, with the latest update submitted on August 14, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
The market implications of this study could be significant for Pfizer’s stock, as positive results may enhance investor confidence and position lorlatinib as a preferred treatment option in the competitive NSCLC market. This could potentially impact the stock performance of competitors in the oncology sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.